Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Evaluering av effekt og sikkerhet av Belantamab Mafodotin, Bortezomib og Deksametason versus Daratumumab, Bortezomib og Deksametason hos deltakere med residiverende/refraktært myelomatose (DREAMM 7)

29. oktober 2026 oppdatert av: GlaxoSmithKline

DRØMME 7: En multisenter, åpen etikett, randomisert fase III-studie for å evaluere effektiviteten og sikkerheten til kombinasjonen av Belantamab Mafodotin, Bortezomib og Deksametason (B-Vd) sammenlignet med kombinasjonen av Daratumumab, Bortezomib og Dexamethason (D-Vdadason) ) hos deltakere med residiverende/refraktært myelomatose

This is a Phase 3, randomized, open-label study designed to evaluate safety and efficacy of belantamab mafodotin in combination with bortezomib/dexamethasone (Arm A) versus daratumumab in combination with bortezomib/dexamethasone (Arm B) in the participants with relapsed recurrent multiple myeloma.

Studieoversikt

Studietype

Intervensjonell

Registrering (Faktiske)

494

Fase

  • Fase 3

Utvidet tilgang

Godkjent for salg til publikum. Se utvidet tilgangspost.

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • New South Wales
      • Camperdown, New South Wales, Australia, 2050
        • GSK Investigational Site
      • Liverpool, New South Wales, Australia, 2170
        • GSK Investigational Site
      • Newcastle, New South Wales, Australia, 2298
        • GSK Investigational Site
      • St Leonards, New South Wales, Australia, 2065
        • GSK Investigational Site
      • Wollongong, New South Wales, Australia, 2500
        • GSK Investigational Site
    • Queensland
      • Benowa, Queensland, Australia, 4217
        • GSK Investigational Site
      • Herston, Queensland, Australia, 4029
        • GSK Investigational Site
    • South Australia
      • Ashford, South Australia, Australia, 5037
        • GSK Investigational Site
    • Victoria
      • Box Hill, Victoria, Australia, 3128
        • GSK Investigational Site
      • Heidelberg, Victoria, Australia, 3084
        • GSK Investigational Site
      • Melbourne, Victoria, Australia, 3004
        • GSK Investigational Site
    • Western Australia
      • Murdoch, Western Australia, Australia, 6150
        • GSK Investigational Site
      • Nedlands, Western Australia, Australia, 6009
        • GSK Investigational Site
      • Roeselare, Belgia, 8800
        • GSK Investigational Site
    • Brussels Capital
      • Jette, Brussels Capital, Belgia, 1090
        • GSK Investigational Site
      • Woluwé-Saint-Lambert, Brussels Capital, Belgia, 1200
        • GSK Investigational Site
    • Oost-Vlaanderen
      • Ghent, Oost-Vlaanderen, Belgia, 9000
        • GSK Investigational Site
      • Joinville, Brasil, 89201-260
        • GSK Investigational Site
      • Natal, Brasil, 59075-740
        • GSK Investigational Site
      • Rio de Janeiro, Brasil, 22775001
        • GSK Investigational Site
      • São Paulo, Brasil, 04537-080
        • GSK Investigational Site
      • São Paulo, Brasil, 05403-000
        • GSK Investigational Site
    • Rio Grande do Sul
      • Porto Alegre, Rio Grande do Sul, Brasil, 90035-903
        • GSK Investigational Site
    • Santa Catarina
      • Florianópolis, Santa Catarina, Brasil, 88020-210
        • GSK Investigational Site
    • Alberta
      • Edmonton, Alberta, Canada, T6G 1Z2
        • GSK Investigational Site
    • Ontario
      • London, Ontario, Canada, N6A 5W9
        • GSK Investigational Site
      • Toronto, Ontario, Canada, M4N 3M5
        • GSK Investigational Site
    • Quebec
      • Montreal, Quebec, Canada, H4J 1C5
        • GSK Investigational Site
    • Arizona
      • Yuma, Arizona, Forente stater, 85364
        • GSK Investigational Site
    • Kansas
      • Mission, Kansas, Forente stater, 66205-2005
        • GSK Investigational Site
    • North Carolina
      • Denver, North Carolina, Forente stater, 80128
        • GSK Investigational Site
    • Ohio
      • Blue Ash, Ohio, Forente stater, 45242-5665
        • GSK Investigational Site
    • Texas
      • Tyler, Texas, Forente stater, 75702
        • GSK Investigational Site
    • Virginia
      • Roanoke, Virginia, Forente stater, 24014
        • GSK Investigational Site
      • Amiens, Frankrike, 80054
        • GSK Investigational Site
      • Caen, Frankrike, 14033
        • GSK Investigational Site
      • Nice, Frankrike, 06200
        • GSK Investigational Site
      • Paris, Frankrike, 75651
        • GSK Investigational Site
      • Rennes, Frankrike, 35033
        • GSK Investigational Site
      • Athens, Hellas, 11528
        • GSK Investigational Site
      • Thessaloniki, Hellas, 54007
        • GSK Investigational Site
    • East Macedonia and Thrace
      • Alexandroupoli, East Macedonia and Thrace, Hellas, 681 00
        • GSK Investigational Site
      • Jerusalem, Israel, 91120
        • GSK Investigational Site
      • Kfar Saba, Israel, 44281
        • GSK Investigational Site
      • Ramat Gan, Israel, 52621
        • GSK Investigational Site
      • Tel Aviv, Israel, 64239
        • GSK Investigational Site
      • Bergamo, Italia, 24127
        • GSK Investigational Site
      • Bologna, Italia, 40138
        • GSK Investigational Site
      • Brescia, Italia, 25123
        • GSK Investigational Site
      • Catania, Italia, 95123
        • GSK Investigational Site
      • Meldola FC, Italia, 47014
        • GSK Investigational Site
      • Milan, Italia, 20133
        • GSK Investigational Site
      • Ravenna, Italia, 48121
        • GSK Investigational Site
      • Roma, Italia, 00168
        • GSK Investigational Site
      • Siena, Italia, 53100
        • GSK Investigational Site
      • Torino, Italia, 10126
        • GSK Investigational Site
      • Aichi, Japan, 467-8602
        • GSK Investigational Site
      • Aichi, Japan, 441-8570
        • GSK Investigational Site
      • Aomori, Japan, 030-8553
        • GSK Investigational Site
      • Ehime, Japan, 790-8524
        • GSK Investigational Site
      • Fukuoka, Japan, 806-8501
        • GSK Investigational Site
      • Fukuoka, Japan, 807-8555
        • GSK Investigational Site
      • Fukuoka, Japan, 810-8563
        • GSK Investigational Site
      • Fukuoka, Japan, 815-8555
        • GSK Investigational Site
      • Gifu, Japan, 503-8502
        • GSK Investigational Site
      • Gunma, Japan, 377-0280
        • GSK Investigational Site
      • Hyōgo, Japan, 670-8540
        • GSK Investigational Site
      • Kanagawa, Japan, 247-8533
        • GSK Investigational Site
      • Kanagawa, Japan, 221-0855
        • GSK Investigational Site
      • Kochi, Japan, 781-8555
        • GSK Investigational Site
      • Nagano, Japan, 392-8510
        • GSK Investigational Site
      • Okayama, Japan, 701-1192
        • GSK Investigational Site
      • Osaka, Japan, 545-8586
        • GSK Investigational Site
      • Osaka, Japan, 530-0012
        • GSK Investigational Site
      • Shizuoka, Japan, 411-8777
        • GSK Investigational Site
      • Beijing, Kina, 100191
        • GSK Investigational Site
      • Beijing, Kina, 100020
        • GSK Investigational Site
      • Changchun, Kina, 130012
        • GSK Investigational Site
      • Guangzhou, Kina, 510060
        • GSK Investigational Site
      • Guangzhou, Kina, 510515
        • GSK Investigational Site
      • Hangzhou, Kina, 310003
        • GSK Investigational Site
      • Jinan, Kina, 250012
        • GSK Investigational Site
      • Nanjing, Kina, 210008
        • GSK Investigational Site
      • Shenyang, Kina, 110001
        • GSK Investigational Site
      • Suzhou, Kina, 215006
        • GSK Investigational Site
      • Tianjin, Kina, 300020
        • GSK Investigational Site
      • Zhengzhou, Kina, 450052
        • GSK Investigational Site
      • Groningen, Nederland, 9713 GZ
        • GSK Investigational Site
    • South Holland
      • Dordrecht, South Holland, Nederland, 3318 AT
        • GSK Investigational Site
      • Christchurch, New Zealand, 8011
        • GSK Investigational Site
      • Dunedin, New Zealand, 9054
        • GSK Investigational Site
      • Takapuna Auckland, New Zealand, 1309
        • GSK Investigational Site
      • Wellington, New Zealand, 6021
        • GSK Investigational Site
      • Chorzów, Polen, 41-500
        • GSK Investigational Site
      • Krakow, Polen, 30510
        • GSK Investigational Site
      • Lodz, Polen, 93-513
        • GSK Investigational Site
      • Lublin, Polen, 20-081
        • GSK Investigational Site
      • Lublin, Polen, 20-090
        • GSK Investigational Site
      • Nowy Sącz, Polen, 33-300
        • GSK Investigational Site
      • Poznan, Polen, 60-569
        • GSK Investigational Site
      • Warsaw, Polen, 02-781
        • GSK Investigational Site
      • Moscow, Russland, 125284
        • GSK Investigational Site
      • Nizhny Novgorod, Russland, 603126
        • GSK Investigational Site
      • Novosibirsk, Russland, 630087
        • GSK Investigational Site
      • Saint Petersburg, Russland, 191024
        • GSK Investigational Site
      • Saint Petersburg, Russland, 197 089
        • GSK Investigational Site
      • Samara, Russland, 443021
        • GSK Investigational Site
      • Saratov, Russland, 410028
        • GSK Investigational Site
      • Ufa, Russland, 450083
        • GSK Investigational Site
      • Barcelona, Spania, 08035
        • GSK Investigational Site
      • Barcelona, Spania, 08916
        • GSK Investigational Site
      • Cáceres, Spania, 10003
        • GSK Investigational Site
      • Gijón, Spania, 33394
        • GSK Investigational Site
      • L'Hospitalet de Llobrega, Spania, 08908
        • GSK Investigational Site
      • MOstoles Madrid, Spania, 28933
        • GSK Investigational Site
      • Madrid, Spania, 28007
        • GSK Investigational Site
      • Madrid, Spania, 31008
        • GSK Investigational Site
      • Murcia, Spania, 30008
        • GSK Investigational Site
      • PamplonaNavarra, Spania, 31008
        • GSK Investigational Site
      • Pozuelo de AlarcOn Madr, Spania, 28223
        • GSK Investigational Site
      • Salamanca, Spania, 37007
        • GSK Investigational Site
      • Bournemouth, Storbritannia, BH7 7DW
        • GSK Investigational Site
      • Cardiff, Storbritannia, CF14 4XW
        • GSK Investigational Site
      • Dundee, Storbritannia, DD1 9SY
        • GSK Investigational Site
      • Leicester, Storbritannia, LE1 5WW
        • GSK Investigational Site
      • London, Storbritannia, W12 0NN
        • GSK Investigational Site
      • Stoke-on-Trent, Storbritannia, ST4 6QG
        • GSK Investigational Site
      • Sutton, Storbritannia, SM2 5PT
        • GSK Investigational Site
      • Pusan, Sør -Korea, 49241
        • GSK Investigational Site
      • Seongnam-si Gyeonggi-do, Sør -Korea, 13620
        • GSK Investigational Site
      • Seoul, Sør -Korea, 06351
        • GSK Investigational Site
      • Seoul, Sør -Korea, 06591
        • GSK Investigational Site
      • Ulsan, Sør -Korea, 44033
        • GSK Investigational Site
      • Brno, Tsjekkia, 625 00
        • GSK Investigational Site
      • Hradec Králové, Tsjekkia, 500 05
        • GSK Investigational Site
      • Ostrava, Tsjekkia, 708 52
        • GSK Investigational Site
      • Prague, Tsjekkia, 128 08
        • GSK Investigational Site
      • Cologne, Tyskland, 50937
        • GSK Investigational Site
    • Baden-Wurttemberg
      • Ulm, Baden-Wurttemberg, Tyskland, 89081
        • GSK Investigational Site
    • Bavaria
      • München, Bavaria, Tyskland, 81377
        • GSK Investigational Site
      • Würzburg, Bavaria, Tyskland, 97080
        • GSK Investigational Site
    • North Rhine-Westphalia
      • Düsseldorf, North Rhine-Westphalia, Tyskland, 40225
        • GSK Investigational Site
    • Thuringia
      • Jena, Thuringia, Tyskland, 07747
        • GSK Investigational Site

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Confirmed diagnosis of multiple myeloma as defined by the International Myeloma Working Group (IMWG) criteria.

  • Previously treated with at least 1 prior line of multiple myeloma (MM) therapy, and must have documented disease progression during or after their most recent therapy.

  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.

  • Must have at least 1 aspect of measurable disease, defined as one of the following;

    1. Urine M-protein excretion >=200 mg per 24-hour, or
    2. Serum M-protein concentration >=0.5 grams per deciliter (g/dL), or
    3. Serum free light chain (FLC) assay: involved FLC level >=10 mg per dL (>=100 mg per liter) and an abnormal serum free light chain ratio (<0.26 or >1.65).
  • All prior treatment-related toxicities (defined by National Cancer Institute Common Toxicity Criteria for Adverse Events [NCI-CTCAE] version 5.0) must be <=Grade 1 at the time of enrollment, except for alopecia.

  • Adequate organ function

Exclusion Criteria:

  • Intolerant to daratumumab.
  • Refractory to daratumumab or any other anti-CD38 therapy (defined as progressive disease during treatment with anti-CD38 therapy, or within 60 days of completing that treatment).
  • Intolerant to bortezomib, or refractory to bortezomib (defined as progressive disease during treatment with a bortezomib-containing regimen of 1.3 mg/m^2 twice weekly, or within 60 days of completing that treatment). Note: participants with progressive disease during treatment with a weekly bortezomib regimen are allowed.
  • Ongoing Grade 2 or higher peripheral neuropathy or neuropathic pain.
  • Prior treatment with anti-B-cell maturation antigen (anti-BCMA) therapy.
  • Prior allogenic stem cell transplant.
  • Any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions, including renal, liver, cardiovascular, or certain prior malignancies.
  • Corneal epithelial disease.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Belantamab mafodotin og Bortezomib pluss deksametason (arm A)

Humanized anti-B-cell maturation antigen (BCMA) antibody/drug conjugate

Proteasome Inhibitor

Synthetic glucocorticoid with anti-tumor activity

Aktiv komparator: Daratumumab og Bortezomib pluss deksametason (arm B)

Proteasome Inhibitor

Synthetic glucocorticoid with anti-tumor activity

Anti-cluster of differentiation 38 [CD-38] monoclonal antibody

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Progression-free Survival (PFS)
Tidsramme: Up to approximately 41 months

PFS is defined as time from randomization until earliest date of disease progression (PD), determined by Independent Review Committee (IRC), according to the International Myeloma Working Group (IMWG) Response Criteria, or death due to any cause. PD= increase of >=25% from lowest value in >=1 of following (serum M-protein [absolute increase >=0.5 grams per deciliter {g/dL}]; serum M-protein increase >=1g/dL [when lowest M-protein >=5g/dL]; urine M-protein [absolute increase >=200 milligrams per 24 hours {mg/24h}]; participants without measurable serum & urine M-protein levels, difference between involved & uninvolved serum free light chains (sFLC) levels [absolute increase >10mg/dL]; appearance of new lesion,>=50% increase from nadir in Sum of the products of the maximal perpendicular diameters of measured lesions (SPD) of >1 lesion, or >=50% increase in longest diameter of previous lesion >1 centimeter (cm) in short axis.

Up to approximately 41 months

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Antall deltakere med unormale øyefunn på oftalmisk undersøkelse
Tidsramme: Inntil 73 måneder
Inntil 73 måneder
Complete Response Rate (CRR)
Tidsramme: Up to 73 months

CRR is defined as percentage of participants with a confirmed complete response or better.

Up to 73 months
Overall Response Rate (ORR)
Tidsramme: Up to 73 months

ORR is defined as percentage of participants with a confirmed partial response or better.

Up to 73 months
Clinical Benefit Rate (CBR)
Tidsramme: Up to 73 months

CBR is defined as percentage of participants with a confirmed minimal response (MR) or better

Up to 73 months
Duration of Response (DoR)
Tidsramme: Up to 73 months

DOR is defined as time from first documented evidence of partial response or better until first documented progression or death, whichever occurs first.

Up to 73 months
Time to Response (TTR)
Tidsramme: Up to 73 months

TTR is defined as time from the date of randomization and the first documented evidence of response (PR or better) among participants who achieve partial response or better.

Up to 73 months
Time to Progression (TTP)
Tidsramme: Up to 73 months

TTP is defined as time from the date of randomization until the earliest date of documented date of disease progression or death, whichever occurs first.

Up to 73 months
Overall Survival (OS)
Tidsramme: Up to 73 months

OS is defined as time from the date of randomization until the date of death due to any cause.

Up to 73 months
Progression-free Survival on Subsequent Line of Therapy (PFS2)
Tidsramme: Up to 73 months

Progression-free survival on subsequent line of therapy is defined as time from randomization to disease progression after initiation of new anti-myeloma therapy or death from any cause, whichever occurs first. If disease progression after new antimyeloma therapy cannot be measured, a PFS event is defined as the date of discontinuation of new anti-myeloma therapy, or death from any cause, whichever is earlier.

Up to 73 months
Minimal Residual Disease (MRD) Negativity Rate
Tidsramme: Up to 73 months

Minimal Residual Disease (MRD) negativity rate is defined as the percentage of participants who are MRD negative status by next generation sequencing (NGS).

Up to 73 months
Number of Participants With Adverse Events (AEs)
Tidsramme: Up to 73 months

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment.

Up to 73 months
Number of Participants With Clinically Significant Changes in Hematology Parameters
Tidsramme: Up to 73 months

Blood samples will be collected for the analysis of hematology parameters.

Up to 73 months
Number of Participants With Clinically Significant Changes in Clinical Chemistry
Tidsramme: Up to 73 months

Blood samples will be collected for the analysis of clinical chemistry parameters.

Up to 73 months
Number of Participants With Clinically Significant Changes in Urine Dipstick
Tidsramme: Up to 73 months

Urine samples will be collected for the urine dipstick analysis.

Up to 73 months
Plasma Concentrations of Belantamab Mafodotin (Total Antibody) at Indicated Time Points
Tidsramme: Up to 73 months

Blood samples will be collected for PK analysis of belantamab mafodotin.

Up to 73 months
Plasma Concentrations of Belantamab Mafodotin (ADC) at Indicated Time Points
Tidsramme: Up to 73 months

Blood samples will be collected for PK analysis of belantamab mafodotin.

Up to 73 months
Plasma Concentrations of Monomethyl Auristatin-F With a Cysteine Linker (Cys-mcMMAF) at Indicated Time Points
Tidsramme: Up to 73 months

Blood samples will be collected for PK analysis of belantamab mafodotin.

Up to 73 months
Number of Participants With Positive Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin
Tidsramme: Up to 73 months

Serum samples collected for the analysis of the presence of ADAs using validated immunoassays. All samples will be tested in screening assay, and positive samples will be further characterized for antibody titers.

Up to 73 months
Titers of ADAs Against Belantamab Mafodotin
Tidsramme: Up to 73 months

Serum samples collected for the analysis of the presence of ADAs using validated immunoassays. All samples will be to be further tested in screening assay, and positive samples will be further to be characterized for antibody titers.

Up to 73 months
Number of Participants With Maximum Post-baseline Change From Baseline in Individual Items of Patient-Reported Outcome Version of the Common Term Criteria for Adverse Events (PRO-CTCAE)
Tidsramme: Up to 73 months

The PRO-CTCAE is a patient-reported outcome measure developed to evaluate symptomatic toxicity in participants on cancer clinical trials. The PRO-CTCAE includes an item library of 124 items representing 78 symptomatic toxicities drawn from the CTCAE.

Up to 73 months
Change From Baseline in Health Related Quality of Life (HRQoL) as Measured by EuropeanOrganization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30)
Tidsramme: Up to 73 months

The EORTC QLQ-C30 includes 30-items with single and multi-item scales. These included five functional scales (physical functioning [PF], role functioning [RF], cognitive functioning [CF], emotional functioning [EF] and social functioning [SF]), three symptom scales (fatigue, pain and nausea/vomiting [N/V]), a global health status (GHS)/ Quality-of-Life (QoL) scale, and six single items (constipation, diarrhoea, insomnia, dyspnoea, appetite loss [AL] and financial difficulties [FD]). Response options are 1 to 4. Scores were averaged and transformed to 0 to 100, a high score for functional scales/ GHS/QoL represent better functioning ability or health-related quality-of-life (HRQoL), whereas a high score for symptom scales/ single items represent significant symptomatology. Baseline was defined as latest pre-dose assessment (Day 1) with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.

Up to 73 months
Change From Baseline in HRQoL as Measured by EORTC IL52
Tidsramme: Up to 73 months

The EORTC Quality of Life Questionnaire 20-item Multiple Myeloma module (QLQMY20) is a supplement to the QLQ-C30 instrument used in participants with multiple myeloma. For the EORTC IL52, disease symptoms domain of the QLQ-MY20 will be used for bone aches or pain, back pain, hip pain, arm or shoulder pain, chest pain, and pain increasing with activity. The individual component scores in the disease symptom domain are averaged and transformed linearly to a score ranging from 0 to100. A high score for disease symptoms represents a high level of symptomatology or problems. A high score represents a high/healthy level of functioning.

Up to 73 months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Etterforskere

  • Studieleder: GSK Clinical Trials, GlaxoSmithKline

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Generelle publikasjoner

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

7. mai 2020

Primær fullføring (Faktiske)

2. oktober 2023

Studiet fullført (Antatt)

8. oktober 2029

Datoer for studieregistrering

Først innsendt

27. januar 2020

Først innsendt som oppfylte QC-kriteriene

27. januar 2020

Først lagt ut (Faktiske)

29. januar 2020

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

13. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

29. oktober 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

IPD-planbeskrivelse

GSK will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere